Avalglucosidase Alfa

READ FIRST - THE UNDER-30 kg BAND IS A US-LABEL CONSTRUCT AND IS WITHHELD. PRIOR VERIFY CARRY-FORWARD: the previous draft of this file was HELD as 'WRONG-JURISDICTION DOSE STRUCTURE, VERIFIED' - a prior session fetched the UK SPC that this bundle lacks (Nexviadyme 100 mg, eMC product 14562) and recorded that it states 'The recommended dose of avalglucosidase alfa is 20 mg/kg of body weight administered once every 2 weeks' for Pompe disease, with 40 mg/kg reserved for INFANTILE-ONSET patients showing an inadequate response, and NO under-30 kg weight band at all. On that reading, publishing the US '<30 kg = 40 mg/kg' rule on a UK page would give DOUBLE the UK-licensed dose to a small adolescent or adult with late-onset disease. That UK figure is NOT in this bundle and is therefore recorded here only as a flag, not as a source: the dose field above publishes solely the 20 mg/kg every-two-weeks figure, which is verbatim in this bundle for patients 30 kg or more and which the recorded UK SPC reading also supports. ACTION: fetch the Nexviadyme UK SPC section 4.2 into the bundle before anything about the under-30 kg patient or the infantile-onset escalation is published. || INDICATION MATCH: this page is enzyme replacement therapy for Pompe disease given by intravenous infusion, and the fetched label doses exactly that (section 8.4 frames the indication as 'the treatment of late-onset Pompe disease'). SCOPE CAUTION: this US label states 'NEXVIAZYME is not approved for the treatment of IOPD' (infantile-onset Pompe disease), whereas the current page's clinical pearls claim infantile-onset use under NICE TA813 - that claim is NOT supported by this bundle and needs the UK SPC / NICE source before it is republished. || VERBATIM DOSING AS THE US LABEL STATES IT (section 2.2), reproduced in full for traceability, with the second band withheld from the dose field for the reason above: 'NEXVIAZYME is administered as intravenous infusion. For patients weighing: 30 kg or more - the recommended dosage is 20 mg/kg (of actual body weight) every two weeks. Less than 30 kg - the recommended dosage is 40 mg/kg (of actual body weight) every two weeks.' || WHY maxDose IS BLANK: no absolute ceiling is stated anywhere in the fetched label - the dosage is expressed only per kilogram of actual body weight, and a per-kg figure cannot serve as an absolute maximum. || PRE-MEDICATION (section 2.1): 'Prior to NEXVIAZYME administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids. Appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, should be readily available during NEXVIAZYME administration.' || REACTION MANAGEMENT (section 2.3), verbatim: 'In the event of a severe hypersensitivity reaction (e.g., anaphylaxis) or severe infusion-associated reaction (IAR), immediately discontinue NEXVIAZYME administration and initiate appropriate medical treatment. In the event of a mild to moderate hypersensitivity reaction or a mild to moderate IAR, consider temporarily holding the infusion for 30 minutes or slowing the infusion rate by 50%... If symptoms persist for longer than 30 minutes despite holding or slowing the infusion, stop the infusion and monitor the patient. Consider re-initiating the infusion on the same day when symptoms subside at 50% of the rate at which the reaction occurred with appropriate pretreatment. If symptoms subside after holding the infusion, resume infusion at 50% of the rate at which the reaction occurred, and subsequently increase the infusion rate every 15 to 30 minutes by 50% as tolerated... Starting with the next infusion, increase the infusion rate until the infusion rate at which the reaction occurred is reached.' || PREPARATION DETAIL (section 2.4): allow vials to stand 30 minutes at 20-25 C before use; inject 10 mL Sterile Water for Injection down the inside wall of each vial, avoiding forceful addition and foaming; 'Gently tilt and roll each vial... Do not invert, swirl, or shake the vial'; each vial yields 100 mg/10 mL (10 mg/mL); round the number of vials up to the next whole number; discard if particles are present or the solution is discoloured. Table 1 (total infusion volume by actual body weight) is truncated at the source-fetch limit and is NOT reproduced here. || ELDERLY (8.5): 'The recommended dosage in geriatric patients is the same as the recommended dosage in younger adult patients.' Studies included 13 patients aged 65-74 and 4 aged 75 or older. || DOSAGE FORM (section 3): 'For injection: 100 mg of avalglucosidase alfa-ngpt as a white to pale-yellow lyophilized powder in a single-dose vial for reconstitution.'

NO PER-KILOGRAM FIGURE IS PUBLISHED FOR CHILDREN, for two independent reasons. (1) WEIGHT-BANDED: section 2.2 gives 20 mg/kg of actual body weight every two weeks for patients weighing 30 kg OR MORE and 40 mg/kg every two weeks for patients weighing LESS THAN 30 kg - the band boundary falls inside the paediatric weight range, so no single per-kg number is valid across it. (2) JURISDICTIONAL DIVERGENCE: a prior verification of this file recorded that the UK SPC (Nexviadyme 100 mg, eMC product 14562 - NOT in this bundle) gives a flat 20 mg/kg every 2 weeks with no under-30 kg band, so the US 40 mg/kg band would be double the UK-licensed dose for a small patient. Do not calculate a paediatric dose from this card: fetch the UK SPC section 4.2 and confirm against a children's formulary and the specialist metabolic team. CONCENTRATION is deliberately null - there is no single mg/mL to divide by: each vial reconstitutes to 100 mg/10 mL (10 mg/mL) but the solution actually infused is further diluted in 5% Dextrose Injection to a final 0.5 to 4 mg/mL (section 2.4). AGE LIMITS (section 8.4 verbatim): 'The safety and effectiveness of NEXVIAZYME for the treatment of late-onset Pompe disease have been established in pediatric patients aged 1 year and older... The safety profile of NEXVIAZYME in pediatric patients 1 to 12 years old with Pompe disease was similar to the safety profile of NEXVIAZYME in older pediatric and adult patients with LOPD. The safety and effectiveness of NEXVIAZYME have not been established in pediatric patients younger than 1 year of age.' The same section states 'NEXVIAZYME is not approved for the treatment of IOPD.' This is US labelling only - verify the dose, the weight bands and any under-18 use against the UK SPC and a children's formulary before administration.